Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
181 Results for "
embryo
" in MedChemExpress (MCE) Product Catalog:
Products (181)
181 Results for "embryo" in MCE Product Catalog:
Cat. No.: HY-W654342
Synonyms: NSC 268508-d20; Neuridine-d20
Cat. No.: HY-117733
CAS No.: 176050-48-9
Cat. No.: HY-150119
CAS No.: 1312013-29-8
Target:
Research Areas:
2'/3'-O-Acetyl-ADP-ribose sodium is an inhibitor of cell division and oocyte maturation. 2'/3'-O-Acetyl-ADP-ribose sodium causes delay or arrest of oocyte maturation and blastomere division in embryos. 2'/3'-O-Acetyl-ADP-ribose sodium is produced by Sir2 family deacetylases during the coupling of histone/protein deacetylation with β-NAD+ cleavage. In neutral or weakly alkaline aqueous solutions, the direct enzymatic product forms of 2'/3'-O-Acetyl-ADP-ribose sodium, namely the 2'-O-acetyl form and the 3'-O-acetyl form, undergo intramolecular lactone exchange reaction and interconvert with each other .
Research Areas:
Potassium dihydrogen phosphate, AR,99.5% is a potassium salt. Potassium dihydrogen phosphate, AR,99.5% activates NF-κB. Potassium dihydrogen phosphate, AR,99.5% upregulates the expression of dental/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) and enhances the mineralization capacity of human periodontal ligament stem cells. Potassium dihydrogen phosphate, AR,99.5% promotes the proliferation of human periodontal ligament stem cells in logarithmic growth phase. Potassium dihydrogen phosphate, AR,99.5% promotes the growth of somatic embryos of Dendrobium Sonia, increases leaf number, leaf length and fresh weight of tissue-cultured seedlings. Potassium dihydrogen phosphate, AR,99.5% is applicable to periodontal disease-related research .
Cat. No.: HY-P75749
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EPHB3; embryonic Kinase 2; Prev. ETK2; Human embryo Kinase 2; Tyro6; EPH-Like Kinase 2; Hek2; EphB3; Tyrosine-Protein Kinase TYRO6; TYRO6; EPH-Like Tyrosine Kinase 2; HEK2; Ephrin Type-B Receptor 3; EPH Receptor B3; EK2
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P75750
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EPHB3; embryonic Kinase 2; Prev. ETK2; Human embryo Kinase 2; Tyro6; EPH-Like Kinase 2; Hek2; EphB3; Tyrosine-Protein Kinase TYRO6; TYRO6; EPH-Like Tyrosine Kinase 2; HEK2; Ephrin Type-B Receptor 3; EPH Receptor B3; EK2
Species:
Rat
Source:
HEK293
Cat. No.: HY-P77931
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: EPHB3; embryonic Kinase 2; Prev. ETK2; Human embryo Kinase 2; Tyro6; EPH-Like Kinase 2; Hek2; EphB3; Tyrosine-Protein Kinase TYRO6; TYRO6; EPH-Like Tyrosine Kinase 2; HEK2; Ephrin Type-B Receptor 3; EPH Receptor B3; EK2
Species:
Human
Source:
HEK293
Cat. No.: HY-P78294
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: EPHB3; embryonic Kinase 2; Prev. ETK2; Human embryo Kinase 2; Tyro6; EPH-Like Kinase 2; Hek2; EphB3; Tyrosine-Protein Kinase TYRO6; TYRO6; EPH-Like Tyrosine Kinase 2; HEK2; Ephrin Type-B Receptor 3; EPH Receptor B3; EK2
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P702711
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: EPHB3; embryonic Kinase 2; Prev. ETK2; Human embryo Kinase 2; Tyro6; EPH-Like Kinase 2; Hek2; EphB3; Tyrosine-Protein Kinase TYRO6; TYRO6; EPH-Like Tyrosine Kinase 2; HEK2; Ephrin Type-B Receptor 3; EPH Receptor B3; EK2
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P705820
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EPHB3; embryonic Kinase 2; Prev. ETK2; Human embryo Kinase 2; Tyro6; EPH-Like Kinase 2; Hek2; EphB3; Tyrosine-Protein Kinase TYRO6; TYRO6; EPH-Like Tyrosine Kinase 2; HEK2; Ephrin Type-B Receptor 3; EPH Receptor B3; EK2
Species:
Human
Source:
sf9 insect cells
Target:
Research Areas:
IWP-3 is a Wnt production inhibitor with an IC50 of 40 nM. IWP-3 also acts as a CK1δ inhibitor, with an IC50 of 1.89 μM against rat full-length CK1δ. IWP-3 inhibits the function of Porcupine (Porcn), thereby blocking the palmitoylation of Wnt proteins, suppressing the canonical Wnt signaling pathway, reducing the proliferative capacity of cancer cells, promoting the differentiation of mesoderm into cardiomyocytes and increasing cardiomyocyte yield. IWP-3 reduces embryonic cell division, alters the cell movement along the anterior-posterior axis of embryos, and causes embryonic shortening. IWP-3 can be used in studies related to cancers such as pancreatic cancer .
Cat. No.: HY-180814
Target:
Research Areas:
SKF-83566-PEG1-pomalidomide is an anti-tumor agent and is formed by the covalent connection of SKF-83566 (HY-103430A) (dopamine D1 receptor antagonist) and Pomalidomide (HY-10984) (immunomodulatory agent). SKF-83566-PEG1-pomalidomide can inhibit cancer cells invasion, migration and colony formation. SKF-83566-PEG1-pomalidomide can inhibit tumor growth and angiogenesis in MDA-MB-231 cell chicken embryo chorioallantoic membrane (CAM) xenograft model. SKF-83566-PEG1-pomalidomide can be used for research of breast cancer .
Cat. No.: HY-184417
CAS No.: 3085883-97-9
Energy-coupling factor-IN-1 is an energy-coupling factor (ECF) transporter inhibitor with an IC50 of 42.84 μM against ECF-FolT2. Energy-coupling factor-IN-1 binds to the interface between the S component and the ECF module, and inhibits the uptake of folic acid and pantothenic acid via the target transporter. Energy-coupling factor-IN-1 acts as a bactericidal agent, exerting rapid and sustained activity for 24 h against Enterococcus faecium, while also acting against Gram-positive bacteria including drug-resistant strains. Energy-coupling factor-IN-1 improves the survival rate of zebrafish embryos infected with Enterococcus faecium. Energy-coupling factor-IN-1 can be used in studies of Gram-positive bacterial infections .
Cat. No.: HY-B1777AR
CAS No.: 306-67-2
Category:
Cat. No.: HY-B1777AS
CAS No.: 1173022-85-9
Target:
Research Areas:
Cat. No.: HY-P4184A
Synonyms: (Ser4,Ile8)-Oxytocin acetate
Target:
Research Areas:
Synonyms: SAN 9789
Research Areas:
Norflurazon (SAN 9789) is a pre-emergence Herbicide. Norflurazon non-competitively inhibits phytoene desaturase by competing with the enzyme cofactor and disrupts carotenoid biosynthesis, thereby leading to chlorophyll photodegradation and chlorosis. Norflurazon inhibits MGDG synthase, CDP-choline phosphotransferase, Omega-3 FAD7 desaturase, and PG delta-3-trans desaturase, and activates LysoPC-acyltransferase and Omega-3 FAD3 desaturase. Norflurazon inhibits photosynthetic membrane organization, mitochondrial respiration, ATP production, PI3K signaling, and ERK1/2 phosphorylation. Norflurazon activates MAPK P38 phosphorylation and ER stress signaling. Norflurazon induces morphological malformations and cardiovascular effects in zebrafish embryos .
Target:
Research Areas:
PolQi1 is a selective inhibitor targeting the Polθ domain of DNA polymerase. PolQi1 inhibits the Polθ-mediated microhomology end joining (TMEJ/alt-EJ) pathway, reducing insertion/deletion (Indels) and imprecise editing events during DNA repair. PolQi1 can enhance the efficiency and accuracy of homology-directed repair (HDR) or Prime editing, and reduce off-target effects; and in combination with DNA-PK inhibitor AZD-7648 (HY-111783), exert efficient genome editing capabilities with dual pathway regulation. PolQi1 can be mainly used in gene editing research (such as CRISPR-Cas9 or Prime editing system optimization) to improve the precision editing efficiency of difficult-to-edit cells (such as primary hepatocytes and mouse embryos) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
